» Articles » PMID: 37365679

Organoids: Approaches and Utility in Cancer Research

Overview
Specialty General Medicine
Date 2023 Jun 26
PMID 37365679
Authors
Affiliations
Soon will be listed here.
Abstract

Organoids are three-dimensional cellular structures with self-organizing and self-differentiation capacities. They faithfully recapitulate structures and functions of in vivo organs as represented by functionality and microstructural definitions. Heterogeneity in in vitro disease modeling is one of the main reasons for anti-cancer therapy failures. Establishing a powerful model to represent tumor heterogeneity is crucial for elucidating tumor biology and developing effective therapeutic strategies. Tumor organoids can retain the original tumor heterogeneity and are commonly used to mimic the cancer microenvironment when co-cultured with fibroblasts and immune cells; therefore, considerable effort has been made recently to promote the use of this new technology from basic research to clinical studies in tumors. In combination with gene editing technology and microfluidic chip systems, engineered tumor organoids show promising abilities to recapitulate tumorigenesis and metastasis. In many studies, the responses of tumor organoids to various drugs have shown a positive correlation with patient responses. Owing to these consistent responses and personalized characteristics with patient data, tumor organoids show excellent potential for preclinical research. Here, we summarize the properties of different tumor models and review their current state and progress in tumor organoids. We further discuss the substantial challenges and prospects in the rapidly developing tumor organoid field.

Citing Articles

Living biobank: Standardization of organoid construction and challenges.

Yang R, Qi Y, Zhang X, Gao H, Yu Y Chin Med J (Engl). 2024; 137(24):3050-3060.

PMID: 39663560 PMC: 11706585. DOI: 10.1097/CM9.0000000000003414.


Tumor organoids for primary liver cancers: A systematic review of current applications in diagnostics, disease modeling, and drug screening.

Qureshi A, Wehrle C, Ferreira-Gonzalez S, Jiao C, Hong H, Dadgar N JHEP Rep. 2024; 6(12):101164.

PMID: 39583095 PMC: 11584567. DOI: 10.1016/j.jhepr.2024.101164.


Bibliometric and visualized analysis of hydrogels in organoids research.

Wang J, Wu J, Zhang J, Guan L, Feng H, Zhu K Regen Ther. 2024; 25:395-404.

PMID: 38435088 PMC: 10905953. DOI: 10.1016/j.reth.2024.02.004.

References
1.
Broutier L, Andersson-Rolf A, Hindley C, Boj S, Clevers H, Koo B . Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. 2016; 11(9):1724-43. DOI: 10.1038/nprot.2016.097. View

2.
Bonazzi V, Kondrashova O, Smith D, Nones K, Sengal A, Ju R . Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. Genome Med. 2022; 14(1):3. PMC: 8751371. DOI: 10.1186/s13073-021-00990-z. View

3.
Li H, Dai W, Xia X, Wang R, Zhao J, Han L . Modeling tumor development and metastasis using paired organoids derived from patients with colorectal cancer liver metastases. J Hematol Oncol. 2020; 13(1):119. PMC: 7650218. DOI: 10.1186/s13045-020-00957-4. View

4.
Demmers L, Kretzschmar K, Van Hoeck A, Bar-Epraim Y, van den Toorn H, Koomen M . Single-cell derived tumor organoids display diversity in HLA class I peptide presentation. Nat Commun. 2020; 11(1):5338. PMC: 7577990. DOI: 10.1038/s41467-020-19142-9. View

5.
Gao D, Vela I, Sboner A, Iaquinta P, Karthaus W, Gopalan A . Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014; 159(1):176-187. PMC: 4237931. DOI: 10.1016/j.cell.2014.08.016. View